1. Home
  2. CAPR vs TRVG Comparison

CAPR vs TRVG Comparison

Compare CAPR & TRVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • TRVG
  • Stock Information
  • Founded
  • CAPR 2005
  • TRVG 2005
  • Country
  • CAPR United States
  • TRVG Germany
  • Employees
  • CAPR N/A
  • TRVG N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • TRVG EDP Services
  • Sector
  • CAPR Health Care
  • TRVG Technology
  • Exchange
  • CAPR Nasdaq
  • TRVG Nasdaq
  • Market Cap
  • CAPR 324.6M
  • TRVG 278.1M
  • IPO Year
  • CAPR N/A
  • TRVG N/A
  • Fundamental
  • Price
  • CAPR $6.18
  • TRVG $3.14
  • Analyst Decision
  • CAPR Strong Buy
  • TRVG Buy
  • Analyst Count
  • CAPR 6
  • TRVG 4
  • Target Price
  • CAPR $23.00
  • TRVG $4.38
  • AVG Volume (30 Days)
  • CAPR 1.0M
  • TRVG 30.9K
  • Earning Date
  • CAPR 11-12-2025
  • TRVG 11-04-2025
  • Dividend Yield
  • CAPR N/A
  • TRVG N/A
  • EPS Growth
  • CAPR N/A
  • TRVG N/A
  • EPS
  • CAPR N/A
  • TRVG N/A
  • Revenue
  • CAPR $13,392,150.00
  • TRVG $592,176,160.00
  • Revenue This Year
  • CAPR N/A
  • TRVG $18.03
  • Revenue Next Year
  • CAPR $7,894.07
  • TRVG $11.32
  • P/E Ratio
  • CAPR N/A
  • TRVG N/A
  • Revenue Growth
  • CAPR N/A
  • TRVG 7.39
  • 52 Week Low
  • CAPR $5.68
  • TRVG $1.61
  • 52 Week High
  • CAPR $22.90
  • TRVG $5.83
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 40.96
  • TRVG 46.20
  • Support Level
  • CAPR $6.05
  • TRVG $2.99
  • Resistance Level
  • CAPR $6.42
  • TRVG $3.20
  • Average True Range (ATR)
  • CAPR 0.34
  • TRVG 0.07
  • MACD
  • CAPR -0.07
  • TRVG 0.01
  • Stochastic Oscillator
  • CAPR 8.95
  • TRVG 53.57

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.

Share on Social Networks: